The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models

被引：3
|
作者：
Song, Kyung W.
Edgar, Kyle A.
Kirkpatrick, Donald S.
Phu, Lilian
Schmidt, Stephen
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Crocker, Lisa
Young, Amy
Sampath, Deepak
Friedman, Lori
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
146
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
    S N Payne
    M E Maher
    N H Tran
    D R Van De Hey
    T M Foley
    A E Yueh
    A A Leystra
    C A Pasch
    J J Jeffrey
    L Clipson
    K A Matkowskyj
    D A Deming
    Oncogenesis, 2015, 4 : e169 - e169
  • [32] TRAF6 interacts with and ubiquitinates PIK3CA to enhance PI3K activation
    Wang, Zixi
    Liu, Yuxiang
    Huang, Song
    Fang, Min
    FEBS LETTERS, 2018, 592 (11): : 1882 - 1892
  • [33] Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer
    Ito, Chie
    Nishizuka, Satoshi S.
    Ishida, Kazuyuki
    Uesugi, Noriyuki
    Sugai, Tamotsu
    Tamura, Gen
    Koeda, Keisuke
    Sasaki, Akira
    JOURNAL OF SURGICAL RESEARCH, 2017, 212 : 195 - 204
  • [34] PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
    Payne, S. N.
    Maher, M. E.
    Tran, N. H.
    Van De Hey, D. R.
    Foley, T. M.
    Yueh, A. E.
    Leystra, A. A.
    Pasch, C. A.
    Jeffrey, J. J.
    Clipson, L.
    Matkowskyj, K. A.
    Deming, D. A.
    ONCOGENESIS, 2015, 4 : e169 - e169
  • [35] Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
    Foley, Tyler M.
    Payne, Susan N.
    Pasch, Cheri A.
    Yueh, Alex E.
    Van De Hey, Dana R.
    Korkos, Demetra P.
    Clipson, Linda
    Maher, Molly E.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Deming, Dustin A.
    MOLECULAR CANCER RESEARCH, 2017, 15 (03) : 317 - 327
  • [36] Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Vasan, Neil
    Razavi, Pedram
    Johnson, Jared L.
    Shao, Hong
    Shah, Hardik
    Antoine, Alesia
    Ladewig, Erik
    Gorelick, Alexander
    Lin, Ting-Yu
    Toska, Eneda
    Xu, Guotai
    Kazmi, Abiha
    Chang, Matthew T.
    Taylor, Barry S.
    Dickler, Maura N.
    Jhaveri, Komal
    Chandarlapaty, Sarat
    Rabadan, Raul
    Reznik, Ed
    Smith, Melissa L.
    Sebra, Robert
    Schimmoller, Frauke
    Wilson, Timothy R.
    Friedman, Lori S.
    Cantley, Lewis C.
    Scaltriti, Maurizio
    Baselga, Jose
    SCIENCE, 2019, 366 (6466) : 714 - +
  • [37] Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models
    Fiascarelli, Alessio
    Carrisi, Corrado
    Merlino, Giuseppe
    Capano, Stefania
    Bisignano, Diego
    Talucci, Simone
    Bressan, Alessandro
    Bellarosa, Daniele
    Bigioni, Mario
    Scaltriti, Maurizio
    Arribas, Joaquin
    Pellacani, Andrea
    Salerno, Massimiliano
    Binaschi, Monica
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Generation of a novel PIK3CA mutated duodenal cancer mouse model and evaluation of PI3K inhibitor therapeutic effects
    Sugimori, Makoto
    Sugimori, Kazuya
    Kanemaru, Yushi
    Tsuchiya, Hiromi
    Suzuki, Yoshimasa
    Nakamori, Yoshinori
    Onodera, Sho
    Tsuyuki, Sho
    Hirotani, Akane
    Sawada, Atsushi
    Hirasawa, Kingo
    Nozaki, Akito
    Numata, Kazushi
    Kunisaki, Chikara
    Maeda, Shin
    CANCER SCIENCE, 2024, 115 : 1893 - 1893
  • [39] Detection of PI3K pathway activation in circulating tumor cells in PIK3CA mutated metastatic breast cancer as a putative predictive biomarker for PI3K inhibitor therapies
    Sharifi, Marina N.
    Sperger, Jamie M.
    Gilsdorf, Cole
    Wolfe, Serena K.
    Parkes, Amanda
    Wisinski, Kari B.
    O'Regan, Ruth M.
    Lang, Joshua M.
    CANCER RESEARCH, 2021, 81 (04)
  • [40] Novel class I PI3K inhibitor CH5132799: disruption of the activated PI3K signaling in PIK3CA mutants confers potent antitumor efficacy
    Yoshida, M.
    Tanaka, H.
    Tanimura, H.
    Fujii, T.
    Sakata, K.
    Ohwada, J.
    Yoshimura, Y.
    Ishii, N.
    Kondoh, O.
    Aoki, Y.
    EJC SUPPLEMENTS, 2010, 8 (07): : 32 - 32
12345